ACS CAN Urges Congress To Fight Proposed Cuts To NIH

Why It Matters

The cuts threaten the pipeline of cancer discoveries and could delay life‑saving therapies, undermining U.S. leadership in biomedical innovation. Protecting NIH funding is critical for sustaining research jobs and public‑health outcomes.

Key Takeaways

• ACS CAN warns NIH cuts will shrink cancer research funding
• FY2027 budget adds modest NCI increase, insufficient to offset cuts
• Congressional appropriators face pressure to protect NIH baseline budget
• Reduced NIH funding could delay clinical trials and new therapies
• Advocacy aims to secure bipartisan support for biomedical research spending

Pulse Analysis

The National Institutes of Health remains the cornerstone of America’s biomedical research enterprise, receiving roughly $45 billion annually to fund everything from basic science to clinical trials. In the FY2027 budget, the administration has earmarked a modest increase for the National Cancer Institute, yet the overall NIH envelope is slated for a cut that could shrink the agency’s capacity by several billion dollars. This paradox reflects a broader fiscal tightening in Washington, where competing priorities such as defense and debt service are crowding out health‑research allocations.

For cancer research, the stakes are especially high. The NCI’s modest boost—estimated at a few hundred million dollars—cannot fully compensate for the loss of funding across the NIH’s portfolio, which supports early‑stage discoveries that often evolve into breakthrough therapies. Reduced grant dollars translate into fewer pilot studies, delayed clinical trials, and slower translation of laboratory findings into patient treatments. Biotech firms that rely on NIH‑funded data may see longer development timelines, potentially raising drug costs and eroding the United States’ competitive edge in oncology innovation.

ACS CAN’s appeal to Congress is part of a coordinated advocacy effort that includes patient groups, academic institutions, and industry partners. By framing NIH cuts as a threat to public health, economic growth, and national security, the coalition hopes to galvanize bipartisan support for a fully funded research budget. If successful, the push could preserve the pipeline of cancer breakthroughs, safeguard research jobs, and reinforce the nation’s reputation as a global leader in medical science.